Edition:
India

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

9.38USD
20 Jul 2018
Change (% chg)

$0.18 (+1.96%)
Prev Close
$9.20
Open
$9.25
Day's High
$9.38
Day's Low
$9.07
Volume
18,787
Avg. Vol
33,630
52-wk High
$14.49
52-wk Low
$8.32

Latest Key Developments (Source: Significant Developments)

Tocagen Entered Amended And Restated Loan And Security Agreement For $26.5 Mln
Thursday, 24 May 2018 

May 23 (Reuters) - Tocagen Inc ::TOCAGEN - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT FOR $26.5 MILLION AS TERM LOANS FUNDED ON EFFECTIVE DATE - SEC FILING.  Full Article

Tocagen Reports Q1 Loss Per Share $0.65
Friday, 11 May 2018 

May 10 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS.Q1 LOSS PER SHARE $0.65.  Full Article

Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China
Thursday, 19 Apr 2018 

April 19 (Reuters) - Tocagen Inc ::TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION.TOCAGEN INC - TOCAGEN ELIGIBLE TO RECEIVE UP TO $127 MILLION IN UPFRONT PAYMENT, DEVELOPMENT AND COMMERCIAL MILESTONES.TOCAGEN - ELIGIBLE TO RECEIVE ADDITIONAL DOUBLE-DIGIT TIERED SALES ROYALTIES UPFRONT AND NEAR-TERM DEVELOPMENT MILESTONES PAYMENTS TOTAL UP TO $20 MILLION.TOCAGEN INC - WILL BE ELIGIBLE FOR ADDITIONAL FUTURE PAYMENTS TOTALING UP TO $111 MILLION UPON MEETING CERTAIN DEVELOPMENT AND COMMERCIAL MILESTONES.TOCAGEN INC - WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION COSTS IN LICENSED TERRITORY.TOCAGEN INC - LICENSE GRANT TO APOLLOBIO IS EXPECTED TO BECOME EFFECTIVE IN Q2 OF 2018.  Full Article

Tocagen Q4 Loss Per Share $0.55
Friday, 9 Mar 2018 

March 8 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS.Q4 LOSS PER SHARE $0.55.‍TOCAGEN ESTIMATES TOTAL CASH USED IN 2018 TO FUND OPERATIONS, CAPITAL EXPENDITURES AND DEBT AMORTIZATION WILL NOT EXCEED $50 MILLION​.‍CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $88.7 MILLION AT DECEMBER 31, 2017 COMPARED TO $31.2 MILLION AT DECEMBER 31, 2016​.  Full Article

Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Tocagen Inc ::TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING.TOCAGEN - ESTIMATE TOTAL CASH USED IN 2018 TO FUND OPERATIONS, CAPITAL EXPENDITURES, DEBT AMORTIZATION TO NOT EXCEED $50.0 MILLION.  Full Article

Tocagen Q3 loss per share $0.50
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Tocagen Inc ::Tocagen reports third quarter 2017 financial and business results.Q3 loss per share $0.50.Tocagen Inc - ‍cash, cash equivalents and marketable securities were $99.6 million at September 30, 2017 compared to $31.2 million at December 31, 2016​.  Full Article

Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Tocagen Inc :Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial.  Full Article

Tocagen receives PRIME designation for Toca 511
Monday, 24 Jul 2017 

July 24 (Reuters) - Tocagen Inc ::Tocagen receives European Medicines Agency Priority Medicines (PRIME) designation for Toca 511 in high grade Glioma.  Full Article

Tocagen Q1 loss per share $4.11
Wednesday, 24 May 2017 

May 23 (Reuters) - Tocagen Inc :Tocagen reports first quarter 2017 financial and business results.Q1 loss per share $4.11.  Full Article

EcoR1 Capital LLC reports 7.6 pct passive stake in Tocagen
Wednesday, 10 May 2017 

May 10 (Reuters) - Tocagen Inc :EcoR1 Capital LLC reports 7.6 percent passive stake in Tocagen Inc as of April 13 - sec filing.  Full Article

BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China

* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION